MAGEA3 and cancer: By fusion of MAGE-A3 peptides with cell-penetrating domains (CPDs), it was possible to achieve more efficient DC membrane penetration and induction of high-level expression of unique DC markers than with MAGE-A3 alone, making such fusion more potent therapeutic cancer vaccine compared with existing MAGE-A3 protein and peptide vaccines [138].